Treating human diseases by inhibiting bacterial enzymes
Implexion Pharma develops innovative strategies to treat selected diseases by targeting gut microbial production of disease-causing substances.
Implexion's first drug candidate is developed against the orphan drug-classified disease primary sclerosing cholangitis (PSC). Today there is no medical treatment for PSC and the patient needs liver transplantation to prevent premature death. Implexion's therapies have a unique opportunity to treat patients and prolong life.
FOR MORE INFORMATION